Arbutus Biopharma Corp. (NASDAQ:ABUS) shot up 5.4% during trading on Wednesday . The company traded as high as $4.32 and last traded at $4.32, with a volume of 59,923 shares trading hands. The stock had previously closed at $4.10.

A number of research firms have commented on ABUS. Leerink Swann reiterated a “buy” rating and issued a $12.00 price target on shares of Arbutus Biopharma Corp. in a research report on Thursday, May 5th. Chardan Capital began coverage on Arbutus Biopharma Corp. in a research report on Monday, May 16th. They set a “sell” rating and a $3.25 target price on the stock. Wedbush restated an “outperform” rating and set a $20.00 target price on shares of Arbutus Biopharma Corp. in a research report on Wednesday, July 20th. Finally, Zacks Investment Research lowered Arbutus Biopharma Corp. from a “buy” rating to a “hold” rating in a research report on Friday, April 22nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $10.96.

The stock has a 50-day moving average of $3.87 and a 200 day moving average of $3.93. The stock’s market cap is $213.04 million.

Arbutus Biopharma Corp. (NASDAQ:ABUS) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by $0.36. Equities research analysts expect that Arbutus Biopharma Corp. will post ($1.49) EPS for the current year.

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.